Royal Philips
(NYSE: PHG)
today announced the expansion of its partnership with Ibex Medical Analytics and the release of its latest Philips IntelliSite Pathology Solution (PIPS).
The Dutch medtech giant says it seeks to accelerate the adoption of AI-enabled digital pathology. The goal is to help health providers address the global shortage of pathologists and the growing number of cancer patients.
Philips and Ibex started a partnership in 2021. PIPS includes Philips’ full portfolio of scanners and Image Management System, — and Ibex’s platform of AI-powered tools for prostate, breast and gastric cancer diagnostics.
“Pathology provides key information for a precise diagnosis. The Philips and Ibex solutions are especially beneficial to the diagnosis of cancer cases because they aid our pathologists in making an accurate and quick diagnosis,” Sam Terese, president and CEO of Alverno Laboratories, said in a news release. “These integrated pathology solutions help us provide the highest possible quality result that any lab can deliver, getting answers back to our clinicians quickly and saving patients sleepless nights, even on complex cases.”
The next-gen Philips IntelliSite Pathology 6.0, includes several new features and AI capabilities. Improved workflows and enhancements include full scan mode for the pathology SG scanner. There is also improved scalability. AI-focused worklists show AI processing status at a case level, and it’s possible to automatically share slides with Ibex AI applications for processing right after digitization.
“The enhanced interoperability between Philips and Ibex platforms, which are now more seamlessly integrated into our diagnostic workflows, will accelerate the adoption of augmented pathology tools in which we strongly believe,” said Stéphane Rossat, director of innovation, science and project management at Medipath France. “PIPS 6.0 promises to facilitate adoption by our physicians, thanks to its streamlined navigation and optimized workflows.”
